The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | - | 1,477 | - | - |
| General and administrative | - | 1,057 | - | - |
| Total operating expenses | - | 2,534 | - | - |
| Amortization of right of use asset | - | 0 | 0 | 0 |
| Other income, net | - | 163 | - | - |
| Net loss | -4,003 | -2,371 | -2,392 | -3,935 |
| Depreciation and amortization | 1 | 1 | 2 | 0 |
| Net gain on disposal of property and equipment | 3 | 0 | 0 | 0 |
| Stock-based compensation | 318 | 274 | 113 | 94 |
| Prepaid expenses and other assets | -74 | -343 | 269 | 165 |
| Lease liability | - | 0 | 0 | 0 |
| Accounts payable | -175 | -80 | 281 | -18 |
| Accrued expenses | -215 | -246 | 180 | 209 |
| Net cash used in operating activities | -4,003 | -2,079 | -2,085 | -3,815 |
| Asset sale proceeds | 3 | 0 | - | - |
| Cash paid for purchase of property and equipment | 0 | 0 | 7 | 5 |
| Net cash provided by (used in) investing activities | 3 | 0 | -7 | -5 |
| Net proceeds from the exercise of warrants | 0 | 2,835 | 200 | 2,720 |
| Net proceeds from the issuance of common stock and warrants | 0 | 9,570 | 1,852 | 6,493 |
| Cash-in-lieu of fractional shares from reverse stock split | - | 0 | - | - |
| Payments to repurchase shares withheld for payroll taxes from restricted stock issuance | - | 0 | 30 | 0 |
| Net cash provided by financing activities | 0 | 12,405 | 2,022 | 9,213 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -4,000 | 10,326 | 5,323 | - |
| Cash, cash equivalents and restricted cash at the beginning of period | 21,031 | 10,705 | 5,382 | - |
| Net increase (decrease) in cash and cash equivalents | - | - | - | 5,393 |
| Cash, cash equivalents and restricted cash at end of period | 17,031 | 21,031 | 10,705 | - |
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. (PHIO)